Actinic Keratosis

Clinical trial for non-melanoma skin cancer and actinic kertosis initiated

Published in Biotech Business Week, April 11th, 2005

Peplin Limited (PEP) announced that it has commenced its program of three phase IIa clinical trials of its proprietary topical product PEP005 Topical for the treatment of actinic keratosis or sun spots (AK) and non-melanoma skin cancer (NMSC).

These phase IIa clinical trials will comprise three separate studies, which are designed to evaluate the ability of PEP005 Topical to treat three diseases - AK and superficial and nodular forms of basal cell carcinoma, the most common form of NMSC.

Peplin's Managing Director and CEO Michael Aldridge said the trials were a world first, with leading dermatologists in major metropolitan centers around Australia...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Business Week

Source: Biotech Business Week (2005-04-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry